Modular Bioreactor System for High-Density Biomolecule Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing and purifying proteins, such as antibodies, are labor-intensive, costly, and inefficient, requiring large-scale equipment and significant resources, which limits scalability and accessibility, especially in therapeutic antibody production.
Innovation Solution
An integrated automated system for cell culture and downstream processing using a high cell density perfusion bioreactor connected to a downstream unit for continuous processing of supernatant, reducing manual handling and resource requirements, and enabling high-yield production with minimal investment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If large-scale batch bioreactors (10000 L) are used for protein production, then product concentration increases, but the system requires large investments in hardware, space, buffer medium, and purified water
Solution Approach 1:
The patent divides the large-scale production system into multiple small modular bioreactors (e.g., 10-100 L each) that can be operated in parallel. This segmentation allows achieving the same total production capacity while reducing individual unit complexity, lowering hardware investment per module, and enabling flexible deployment in smaller spaces. The modular approach also reduces the amount of buffer medium and purified water needed per unit.
Solution Approach 2:
The patent implements a nested configuration where multiple small bioreactors are integrated within a compact system architecture. The bioreactors are arranged in a space-efficient manner, with shared control systems and fluid handling infrastructure, effectively nesting functional components to reduce overall space requirements while maintaining high product concentration capabilities.
2Adaptability or versatility
If conventional manual methods (T-flasks, roller bottles, stirred bottles) are used for cell culture, then flexibility in operation is maintained, but labor intensity increases and scalability is limited
Solution Approach 1:
The patent implements automated control systems that enable the bioreactors to self-regulate critical parameters such as temperature, pH, dissolved oxygen, and agitation speed. The system includes automated sampling, monitoring, and adjustment mechanisms that reduce manual intervention while maintaining operational flexibility. This self-service capability significantly reduces labor intensity and enables scalable production without proportionally increasing manual operations.
3Productivity
If batch processing with 8-hour harvest cycles is used, then production throughput increases, but yield loss occurs during clarification and medium exchange requires large amounts of buffer medium
Solution Approach 1:
The patent transitions from batch processing to continuous perfusion culture mode, where fresh medium is continuously supplied and cell-containing supernatant is continuously removed. This continuous operation maintains optimal growth conditions throughout the process, eliminating the yield loss associated with batch clarification steps. The continuous perfusion also reduces buffer medium consumption by maintaining steady-state conditions without requiring large-volume medium exchanges.
4Productivity
If high cell density culture (≥50 million cells/ml) is achieved, then product output increases, but oxygen transfer and nutrient supply become limiting factors
Solution Approach 1:
The patent employs dynamic control of agitation speed, aeration rate, and perfusion flow rate to optimize oxygen transfer and nutrient supply at high cell densities. The system automatically adjusts these parameters in response to real-time measurements of dissolved oxygen and cell density, maintaining optimal mass transfer conditions throughout the culture process. This dynamic adjustment prevents oxygen and nutrient limitation while sustaining high productivity.
Data Source
AI summary
An automated method for the production of cells and/or biomolecules such as protein or peptides includes culturing cells in at least one high cell density bioreactor, thereby fluidly connecting said bioreactor with a culture medium supply and a gas or gaseous mixture; fluidly connecting said bioreactor with a downstream unit; and growing cells to a density at least 50 million cells per ml. The total volume of the bioreactor is at least 10 liters. A system suitable for implementation of the automated method above is a small-scale and cupboard-sized system, which can be placed in a portable clean room.